Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antipsychotic discontinuation in first-episode psychosis
ACTRN12610000954022Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of haloperidol, olanzapine, risperidone, quetiapine and ziprasidone in psychosis (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to discontinuation of randomized antipsychotic at 12 months. Started Jan 2002; status: completed.
02
Drugs
haloperidololanzapinerisperidonequetiapineziprasidone
03
Conditions
psychosis
Beyond the preview
Go deeper on ACTRN12610000954022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000954022.